tirzepatide not on shortage list Compounders protest as FDA removes off FDA says tirzepatide shortage is

Incorrect dosing risks: inconsistent potency increases the likelihood of overdosing or underdosing, both of which compromise safety

Say goodbye to rough, dry skin and hello to a smoother, healthier you

however, when severe enough, the medication may need to be discontinued

Retatrutide 20 mg, as a single peptide molecule, shows activity against three important molecular targets: - glucagon-like peptide-1 (GLP-1) receptor - glucose-dependent insulinotropic polypeptide (GIP) receptor - glucagon receptor (GCGR) This receptor profile makes Triple G 20 mg a valuable research material for laboratories working on endocrinology, metabolism and the molecular basis of metabolic diseases

doi: 10.1210/jc.2006-1584

2008;57 Suppl 1:S135-S141